A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-susceptible Staphylococcus aureus Bloodstream Isolates Possessing Detectable mecA by a Commercial PCR Assay Compared to Patients with Methicillin-resistant Staphylococcus aureus Bloodstream Isolates [PublishAheadOfPrint]

mecA-positive Staphylococcus aureus isolates phenotypically susceptible to cefoxitin (mecA-MSSA) have been identified. We describe treatment and outcomes among patients with mecA-MSSA bloodstream infections (BSI) and MRSA BSI patients matched 1:1 on age, BSI origin and BSI type (n=17 per group). Compared to MRSA BSI patients, mecA-MSSA BSI patients more often experienced clinical failure (58.8% and 11.8%, p=0.010), driven largely by persistent bacteremia (35.3% and 11.8%). mecA-MSSA BSI patients may be at higher risk for poor clinical outcomes.

http://ift.tt/2yPUkCJ